XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company that became a publicly reporting entity following its SPAC business combination, with the SEC filing record carried under CIK 0001697805. The company operates in the oncology-focused pharmaceutical sector, advancing a pipeline of cancer therapeutics. Its November 2019 Form 10-Q quarterly filing reflects its status as a post-merger reporting company subject to full SEC disclosure requirements. The filing was submitted in 2019, placing the de-SPAC transition in that period of heightened activity across life-sciences blank-check vehicles. For full filing history, sponsor details, and deal-level analytics on Xynomic and hundreds of comparable transactions, sign up for complete data access at SpacDesk.